Therapeutic Efficacy of p53 Restoration in Mdm2-Overexpressing Tumors

The p53 (TP53) tumor suppressor is the most frequently mutated gene in human cancers. Restoring expression of wild-type p53 has led to tumor growth suppression in a variety of tumor models that are p53 deficient. Other mechanisms, for example, upregulation of Mdm2, exist in tumors to inactivate the p53 pathway. Mdm2, an E3 ubiquitin ligase that targets p53 for proteasomal degradation, is present at high levels in many tumors with wild-type p53. In this study, the effects of restoring p53 activity were probed in Mdm2-overexpressing tumors genetically using animal models. Here, it was demonstrated that elevated levels of Mdm2 and decreased levels of p53 act additively to dampen p53 activity in DNA damage response and tumor development. Our data further indicate that restoration of wild-type p53 expression in Mdm2-overexpressing angiosarcomas results in tumor stasis and regression in some cases. Finally, it was determined that restored p53 suppressed cell proliferation but did not elicit apoptosis in the Mdm2-overexpressing angiosarcomas. Implications: Restoration of wild-type p53 expression in Mdm2-overexpressing tumors suppresses tumor growth, which represents a potential clinical strategy to treat tumors with high levels of Mdm2. Visual Overview: http://mcr.aacrjournals.org/content/12/6/901/F1.large.jpg. Mol Cancer Res; 12(6); 901–11. ©2014 AACR. Visual Overview

[1]  V. Pant,et al.  The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity , 2013, Genes & development.

[2]  Anil K Sood,et al.  Poor survival with wild-type TP53 ovarian cancer? , 2013, Gynecologic oncology.

[3]  Barbara Costa,et al.  Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor , 2013, PloS one.

[4]  Stine H. Kresse,et al.  Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma , 2013, Cancer.

[5]  W. El-Deiry,et al.  p21WAF1 and tumourigenesis: 20 years after , 2013, Current opinion in oncology.

[6]  Guillermina Lozano,et al.  Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy , 2012, Clinical Cancer Research.

[7]  Drew M. Lowery,et al.  AATF/Che‐1 acts as a phosphorylation‐dependent molecular modulator to repress p53‐driven apoptosis , 2012, The EMBO journal.

[8]  V. Baladandayuthapani,et al.  Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA , 2012, Molecular Cancer Therapeutics.

[9]  A. E. Silva,et al.  Alterations of the TP53 Gene in Gastric and Esophageal Carcinogenesis , 2012, Journal of biomedicine & biotechnology.

[10]  Thelma Thompson,et al.  Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.

[11]  J. Blay,et al.  A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. , 2012 .

[12]  L. Vassilev,et al.  Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia , 2011 .

[13]  C. Michiels,et al.  Reciprocal influence of the p53 and the hypoxic pathways , 2011, Cell Death and Disease.

[14]  Bin Bao,et al.  Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors , 2011, Oncotarget.

[15]  C. Maki,et al.  Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 , 2011, Oncogene.

[16]  A. El‐Naggar,et al.  Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. , 2011, The Journal of clinical investigation.

[17]  G. Lozano,et al.  Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo , 2011, The Journal of pathology.

[18]  L. Vassilev,et al.  A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL) , 2010 .

[19]  E. Brambilla,et al.  The ARF tumor suppressor: Structure, functions and status in cancer , 2010, International journal of cancer.

[20]  Arnold J Levine,et al.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. , 2010, Cancer cell.

[21]  J. Manfredi The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.

[22]  P. Ouillette,et al.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.

[23]  I. Okayasu,et al.  Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. , 2010, Human pathology.

[24]  Jeremy R Stuart,et al.  Low-Dose Radiation-Induced Senescent Stromal Fibroblasts Render Nearby Breast Cancer Cells Radioresistant , 2009, Radiation research.

[25]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[26]  G. Lozano,et al.  Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. , 2009, Differentiation; research in biological diversity.

[27]  J. Baselga,et al.  Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[29]  H. Okano,et al.  The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival , 2008, Cell Death and Differentiation.

[30]  Guillermina Lozano,et al.  Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities , 2008, Molecular Cancer Research.

[31]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[32]  C. Blattner,et al.  JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies , 2008 .

[33]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[34]  D. Notterman,et al.  MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers , 2008, Molecular Cancer Research.

[35]  D. Vaux,et al.  Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans , 2008, Cell Death and Differentiation.

[36]  Guillermina Lozano,et al.  Loss of Mdm4 Results in p53-Dependent Dilated Cardiomyopathy , 2007, Circulation.

[37]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[38]  G. Lozano,et al.  Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development , 2007, Molecular and Cellular Biology.

[39]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[40]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[41]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[42]  G. Wahl,et al.  Mouse Mutants Reveal that Putative Protein Interaction Sites in the p53 Proline-Rich Domain Are Dispensable for Tumor Suppression , 2006, Molecular and Cellular Biology.

[43]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[44]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[45]  A. Vercelli,et al.  High Levels of Cre Expression in Neuronal Progenitors Cause Defects in Brain Development Leading to Microencephaly and Hydrocephaly , 2006, The Journal of Neuroscience.

[46]  M. Dai,et al.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. , 2006, Neoplasia.

[47]  Hiroyuki Yamamoto,et al.  Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells , 2006, Journal of Medical Genetics.

[48]  M. Kitayner,et al.  Structural basis of DNA recognition by p53 tetramers. , 2006, Molecular cell.

[49]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[50]  G. Wahl,et al.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.

[51]  G. Wahl,et al.  Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.

[52]  Geng-Hung Liu,et al.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Antonina Andreeva,et al.  Core domain interactions in full-length p53 in solution , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[55]  A. Fersht,et al.  Comparative binding of p53 to its promoter and DNA recognition elements. , 2005, Journal of molecular biology.

[56]  A. Bocian,et al.  A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. , 2005, Journal of experimental & clinical cancer research : CR.

[57]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[58]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[59]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[60]  C. Cordon-Cardo,et al.  MDM2 and prognosis. , 2004, Molecular cancer research : MCR.

[61]  T. Hupp,et al.  The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53 , 2003, Molecular and Cellular Biology.

[62]  Michael Berger,et al.  Apoptosis - the p53 network , 2003, Journal of Cell Science.

[63]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[64]  T. Greiner,et al.  Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.

[65]  C. Fenoglio-Preiser,et al.  TP53 and gastric carcinoma: A review , 2003, Human mutation.

[66]  S. Murray,et al.  The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response , 2002, Nature.

[67]  S. Volinia,et al.  The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults , 2002, Nature.

[68]  K. Helin,et al.  Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.

[69]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[70]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[71]  Andrew P McMahon,et al.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. , 2002, Developmental biology.

[72]  D. Troyer,et al.  Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. , 2002, Cancer research.

[73]  T. Sugai,et al.  p53 gene mutation and MDM2 overexpression in a case of primary malignant fibrous histiocytoma of the jejunum , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[74]  R. Iggo,et al.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Korsmeyer,et al.  Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis , 2001, Molecular and Cellular Biology.

[76]  A. Berns,et al.  Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[77]  A. El‐Naggar,et al.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 , 2001, Oncogene.

[78]  M. Murphy,et al.  The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.

[79]  P. Chène,et al.  The role of tetramerization in p53 function , 2001, Oncogene.

[80]  L. Donehower,et al.  Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing , 2001, Toxicologic pathology.

[81]  D. Wiederschain,et al.  Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. , 2000, The American journal of pathology.

[82]  B. Wasylyk,et al.  MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis , 2000, The EMBO journal.

[83]  N. Little,et al.  Hdmx stabilizes Mdm2 and p53. , 2000, The Journal of biological chemistry.

[84]  Mong-Hong Lee,et al.  Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.

[85]  R. Schneider-Stock,et al.  Mdm2 Gene Amplification in Gastric Cancer Correlation with Expression of Mdm2 Protein and p53 Alterations , 2000, Modern Pathology.

[86]  T. Koyama,et al.  MDM2 Overexpression with Alteration of the p53 Protein and Gene Status in Oral Carcinogenesis , 2000, Japanese journal of cancer research : Gann.

[87]  V. Zoumpourlis,et al.  Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs) , 2000, Molecular medicine.

[88]  D. Troyer,et al.  Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors , 2000, Oncogene.

[89]  M. Jackson,et al.  MdmX Protects p53 from Mdm2-Mediated Degradation , 2000, Molecular and Cellular Biology.

[90]  I. Ganly,et al.  p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy , 2000, British Journal of Cancer.

[91]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[92]  G. Wahl,et al.  p53 regulation by post-translational modification and nuclear retention in response to diverse stresses , 1999, Oncogene.

[93]  T. McDonnell,et al.  Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice , 1999, The Journal of pathology.

[94]  C. Harris,et al.  GADD45 induction of a G2/M cell cycle checkpoint. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[95]  D. Felsher,et al.  Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[96]  B. Wasylyk,et al.  MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice , 1999, Oncogene.

[97]  L. Donehower,et al.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[98]  L. Hengst,et al.  Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication , 1998, Molecular and Cellular Biology.

[99]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[100]  G. Chu Double Strand Break Repair* , 1997, The Journal of Biological Chemistry.

[101]  D. Lane,et al.  p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding , 1997, Oncogene.

[102]  S. Berger,et al.  CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. , 1997, Cancer research.

[103]  J. Landers,et al.  Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. , 1997, Cancer research.

[104]  Wenyi Wei,et al.  Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. , 1997, Science.

[105]  H. Sakamoto,et al.  Effect of Phosphorylation on Tetramerization of the Tumor Suppressor Protein p53 , 1997, Journal of protein chemistry.

[106]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[107]  G. Lozano,et al.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.

[108]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[109]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[110]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[111]  D. Spandidos,et al.  A MOLECULAR AND IMMUNOHISTOCHEMICAL STUDY OF THE MDM2 PROTEIN ISOFORMS AND p53 GENE PRODUCT IN BRONCHOGENIC CARCINOMA , 1996, The Journal of pathology.

[112]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[113]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[114]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[115]  K. Kinzler,et al.  Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.

[116]  D. Haines,et al.  Analysis of p53 and mdm‐2 expression in 18 patients with Sézary syndrome , 1996, British journal of haematology.

[117]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[118]  S. Elledge,et al.  Inhibition of cyclin-dependent kinases by p21. , 1995, Molecular biology of the cell.

[119]  T. Kinoshita,et al.  The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.

[120]  G. Wahl,et al.  DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. , 1994, Genes & development.

[121]  J. Roth,et al.  Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. , 1994, Journal of the National Cancer Institute.

[122]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[123]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[124]  T. Halazonetis,et al.  Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. , 1993, The EMBO journal.

[125]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[126]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[127]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[128]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[129]  P. Friedman,et al.  The p53 protein is an unusually shaped tetramer that binds directly to DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[130]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[131]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[132]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[133]  A. Levine,et al.  Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.

[134]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[135]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[136]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[137]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[138]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[139]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[140]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[141]  L. Kaczmarek,et al.  Growth-dependent expression of human Mr 53,000 tumor antigen messenger RNA in normal and neoplastic cells. , 1986, Cancer research.

[142]  V. Rotter,et al.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.

[143]  L. Old,et al.  Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[144]  F. McCormick,et al.  Lymphocyte stimulation: concanavalin A induces the expression of a 53K protein. , 1980, Cell biology international reports.

[145]  P. May,et al.  Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.

[146]  M. Martin,et al.  Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells , 1979, Journal of virology.

[147]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[148]  J. Marine MDM2 and MDMX in cancer and development. , 2011, Current topics in developmental biology.

[149]  L. Vassilev,et al.  Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  David P. Lane,et al.  Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.

[151]  R. Eisenman,et al.  Tumor suppression and normal aging in mice with constitutively high p53 activity. , 2006, Genes & development.

[152]  A. Multani,et al.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.

[153]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[154]  K. Aldape,et al.  Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[155]  J. Bourhis,et al.  British Journal of Cancer , 2001 .

[156]  K. Ishak,et al.  Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[157]  C. Bellamy,et al.  p53 and apoptosis. , 1997, British medical bulletin.

[158]  J. Roth,et al.  Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. , 1993, Human gene therapy.

[159]  V. Rotter,et al.  Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. , 1987, Oncogene.